Liver transplantation for chronic C hepatitis, significance for antivirus treatments

Česká verzia

Authors: J. Šperl ¹ ; S. Fraňková ¹ ; P. Trunečka ²
Published in the journal: Gastroent Hepatol 2013; 67(5): 407-412
Category: Hepatology: Original Article

Summary

Chronic hepatitis C nowadays represents the most common indication for liver transplantation (LTx) worldwide. The survival rate of HCV patients after LTx is worse than that of patients transplanted for cirrhosis of other aetiology owing to HCV graft reinfection leading to the development of recurrent hepatitis C in the liver graft. We retrospectively reviewed 149 patients, 50 females and 99 males, who underwent LTx in the period from 1995 to 2013 of a total of 957 liver graft recipients who underwent LTx within the same period (HCV represents 15.6% of all LTx indications). The average age of the patients was 53 (ranging from 15 to 69). One hundred and forty-eight patients were infected with genotype 1b, only one patient had genotype 3a. Forty-eight patients had a small hepatocellular carcinoma. Eighty-two patients of 149 were given antiviral treatment. The survival of HCV patients was worse compared to the group of patients with non-HCV cirrhosis as well as of all other patients; three years 79.3%, five years 72.5% and 10 years 62.9% (non-HCV cirrhosis 89.4%, 87.2% and 79.7%; p < 0.001, all other patients 88.2%, 85.8% and 78.8 %; p < 0.001). Thirty-two of 82 patients achieved a sustained virological response (SVR) after administration of a combined antiviral therapy (39%). The survival of patients who achieved an SVR (100%, 92.0% and 92.0%) was significantly better than the survival of patients without SVR (85.7%, 76.9% and 63.3%; p = 0.0026), the worst was the survival of patients who were not treated due to a contraindication to therapy (63.1%, 58.3% and 47.0%, p < 0.001). Eradication of the HCV infection and SVR significantly increased the survival of patients transplanted for HCV infection but the number of patients, who are not eligible for peginterferon α-based therapy, still remains high.

Key words:
chronic hepatitis C – recurrence – liver transplantation – antiviral treatment – survival

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
2. 9. 2013

Accepted:
27. 9. 2013

Zdroje

1. Charlton M, Ruppert K, Belle SH et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10(9): 1120–1130.

2. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (Suppl 2): S36–S44.

3. Forman LM, Lewis JD, Berlin JA et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122(4): 889–896.

4. Neumann UP, Berg T, Bahra M et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77(2): 226–231.

5. Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36(1): 202–210.

6. Roche B, Sebagh M, Canfora ML et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14(12): 1766–1777.

7. Picciotto FP, Tritto G, Lanza AG et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46(3): 459–465.

8. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24(2): 289–293.

9. Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28(3): 823–830.

10. Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334(13): 815–820.

11. Zekry A, Whiting P, Crawford DH et al. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl 2003; 9(4): 339–347.

12. Charlton MR, Thompson A, Veldt BJ et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53(1): 317–324.

13. Fukuhara T, Taketomi A, Motomura T et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139(5): 1577–1585.

14. Humar A, Kumar D, Raboud J et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2(5): 461–466.

15. Mazzaferro V, Tagger A, Schiavo M et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33(1–2): 1355–1357.

16. Shergill AK, Khalili M, Straley S et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5(1): 118–124.

17. Wang CS, Ko HH, Yoshida EM et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6(7): 1586–1599.

18. Berenguer M, Aguilera V, Prieto M et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15(7): 738–746.

19. Berenguer M, Palau A, Fernandez A et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12(7): 1067–1076.

20. Chalasani N, Manzarbeitia C, Ferenci P et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41(2): 289–298.

21. Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124(3): 642–650.

22. Coilly A, Roche B, Dumortier J et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation, a multicenter experience. J Hepatol 2013; doi: 10.1016/j.jhep.2013.08.018.

23. Adam R, Karam V, Delvart V et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57(3): 675–688.